///选项卡2

研究文章

环氧化酶-2的表达是结肠直肠癌晚期复发的预测指标

表2

根据复发患者COX-2表达的临床和病理特点。


变量	总病人()	cox - 2 - ()	cox - 2阳性()	价值

年龄(岁)				0.200
< 70	80例(81.6%)	40 (76.9%)	40 (87.0%)
≥70	18 (18.4%)	12 (23.1%)	6 (13.0%)
性别				0.267
男性	56 (57.1%)	27 (51.9%)	29 (63.0%)
女	42 (42.9%)	25 (48.1%)	17 (37.0%)
肿瘤的位置				0.725
右结肠	25 (25.5%)	13 (25.0%)	12 (26.1%)
左结肠	16 (16.3%)	9 (17.3%)	7 (15.2%)
直肠	57 (58.2%)	30 (57.7%)	26 (58.7%)
肿瘤大小				0.286
< 5厘米	33 (33.7%)	20 (38.5%)	13 (28.3%)
≥5厘米	65例(66.3%)	32 (61.5%)	33 (71.7%)
生产总值(gdp)类型				0.680
Fungating	44 (44.9%)	22 (42.3%)	22 (47.8%)
渗透性的	46 (46.9%)	25 (48.0%)	21 (45.6%)
未知的	8 (8.2%)	5 (9.6%)	3 (6.5%)
细胞类型				1.000
Nonmucinous	93例(94.9%)	49 (94.2%)	44 (95.7%)
粘液性	5 (5.1%)	3 (5.8%)	2 (4.3%)
分化				0.291
WD	4 (4.1%)	2 (3.8%)	2 (4.3%)
医学博士	75例(76.5%)	43 (82.7%)	32 (69.6%)
PD	19 (19.4%)	7 (13.5%)	12 (26.1%)
淋巴入侵				0.190
缺席	20 (20.4%)	8 (15.4%)	12 (26.1%)
现在	78例(79.6%)	44 (84.6%)	34 (73.9%)
血管侵犯				1.000
缺席	98例(100%)	52 (100%)	46 (100%)
现在	0 (0%)	0 (0%)	0 (0%)
T类别				0.840
T1	0 (0%)	0 (0%)	0 (0%)
T2	3 (3.1%)	1 (1.9%)	2 (4.3%)
T3	92例(93.9%)	49 (94.2%)	43 (93.5%)
T4	3 (3.1%)	2 (3.8%)	1 (2.2%)
N类别				0.479
N0	22 (22.4%)	11 (21.2%)	11 (23.9%)
N1	27 (27.6%)	17 (32.7%)	10 (21.7%)
N2	49 (50.0%)	24 (46.2%)	25 (54.3%)
阶段				0.713
我	1 (1%)	0 (0%)	1 (2.2%)
2	22 (22.4%)	11 (21.2%)	11 (23.9%)
3	75例(76.6%)	41 (78.8%)	34 (73.9%)
复发时间(月)	27.6±24.8	21.9±17.4	34.1±30.0	0.019
递归式				0.001
早期(≤3岁)	71例(72.4%)	45 (86.5%)	26 (56.5%)
晚(> 3年)	27 (27.6%)	7 (13.5%)	20 (43.5%)

我们致力于尽快、安全地分享与COVID-19有关的发现。任何提交COVID-19论文的作者，请在以下地址通知我们help@hindawi.com以确保他们的研究被快速跟踪，并尽快在预印本服务器上可用。我们将为已接受的COVID-19相关文章提供不受限制的出版费用减免。注册在这里作为审稿人，帮助快速跟踪新提交的内容。